Trial Profile
Incidence of brain metastasis and outcomes in patients with RET-rearranged lung cancers treated with multi-kinase inhibitor therapy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 Jun 2017
Price :
$35
*
At a glance
- Drugs Alectinib (Primary) ; Cabozantinib (Primary) ; Lenvatinib (Primary) ; Ponatinib (Primary) ; Vandetanib (Primary)
- Indications Lung cancer
- Focus Adverse reactions; Therapeutic Use
- 02 Jun 2017 Results assessing baseline brain metastasis and outcomes with multikinase inhibitor therapy in patients with RET-rearranged lung cancers from a global registry and a phase II trial (NCT01639508), presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 02 Jun 2017 New trial record